Q4 2025 Lifecore Biomedical Inc Earnings Call Transcript
Key Points
- Lifecore Biomedical Inc (LFCR) achieved a 10% increase in revenue for the fourth quarter of 2025 compared to the prior-year quarter, and a 20% increase for the seven-month transition period.
- The company successfully qualified its 5-head isolator filler for the European and Asian markets, supporting a significant increase in aseptic fill/finish demand expected in 2027.
- Lifecore added several new high-value programs to its late-stage pipeline, including two commercial site transfers, which are expected to generate commercial revenue within 24 to 30 months.
- The company improved its adjusted EBITDA margins through cost improvement initiatives and expects further enhancements with the launch of a new enterprise resource planning system.
- Lifecore's business development strategy has been revamped, leading to five new programs in the transition period and a strong pipeline of potential future projects.
- The expected launch timeline for Lifecore's late-stage programs has been adjusted from 2026-2029 to 2027-2030 due to external factors such as customer development plan changes and financing challenges.
- The company anticipates a net loss for 2026, with guidance indicating a range of $28.9 million to $33.4 million.
- A customer decision to build excess hyaluronic acid inventory in 2025 will result in a $10 million revenue reduction in 2026.
- Lifecore faces the anticipated loss of a customer due to a change in that customer's supply chain strategy, impacting 2026 revenue.
- The commercial launch of a program targeted for 2026 has been delayed to 2028 due to customer funding challenges.
Good day and welcome to the Lifecore Biomedical fourth quarter 2025 earnings conference call.
(Operator Instructions)
Please note this call is being recorded.
I would like to turn the call over to Stephanie Diaz, Manager of Investor Relations. Please go ahead.
Good morning and thank you for joining us.
Today, Lifecore Biomedical will provide its earnings results for the fourth quarter and transition period ending December 31, 2025, and a corporate update. As the company has recently changed its fiscal year end to align with the calendar year, we will be comparing our 2025 results to the closest comparable period in the prior year. Today, we will be comparing our fourth quarter ended December 31, 2025, with the previously reported quarter ended November 24, 2024. We will be comparing our seven-month transition period ended December 31, 2025, with the unaudited seven-month period ended December 31, 2024.
Hosting the call today from Lifecore
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
